Breaks Categories: News

MondaySep 21, 2020 11:10 am

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Engagement of Tailwinds Research Group, Video Update and Strategic Advisory Board Appointment

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, on Friday announced its engagement of Tailwinds Research Group to provide digital content distribution for the company. According to the update, the engagement will cover a 1-year term, at US$2,500/month with 100,000 stock options provided at C$0.88/option. In addition, LexaGene today released a video message from its founder and CEO, Dr. Jack Regan, that highlighted the company’s progress toward commercial sales and announced the appointment of Dr. Shelley Rankin to LexaGene’s Scientific Advisory Board. “As we approach sales, I’m very pleased to…

Continue Reading

FridaySep 18, 2020 12:25 pm

BioMedNewsBreaks – IDEAYA Biosciences Inc. (NASDAQ: IDYA) Announces ‘Transformational’ Second Quarter

IDEAYA Biosciences (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, recently provided a business update and announced financial results for the second quarter ended June 30, 2020. "This quarter was transformational for IDEAYA. We have cash runway into 2024, with quarter-end cash, cash equivalents and marketable securities of $172.0 million supplemented by $127.5 million aggregate gross proceeds received subsequently, including $100 million non-dilutive upfront cash and $20 million private placement equity investment from GSK,” said Yujiro S. Hata, CEO and president of IDEAYA Biosciences, in the press release. “In addition, through our…

Continue Reading

ThursdaySep 17, 2020 10:13 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Slated to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, announced it will be one of the companies appearing at this year’s online  Oppenheimer Fall Healthcare Life Sciences & MedTech Summit; the event is scheduled for Tuesday, Sept. 2020. The company’s CEO John Climaco will make the virtual presentation as well as hold one-on-one virtual investor meetings throughout the event. The summit will begin at 10 a.m. EDT, and a replay of Climaco’s presentation will be available on the company's website for 90 days after the…

Continue Reading

WednesdaySep 16, 2020 2:38 pm

BioMedNewsBreaks – Revive Therapeutics Ltd. (CSE: RV) (OTC: RVVTF) Receives IRB Approval for Bucilliamine COVID-19 Treatment Program

Revive Therapeutics (CSE: RVV) (OTC: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced that is has received approval from the independent Institutional Review Board ("IRB") for one of its programs. The program is Revive’s expanded access protocol (“EAP”) for compassionate use of Bucillamine in the treatment of COVID-19. The EAP comprises a multi-center, open-label study of Bucillamine in hospitalized patients suffering from severe COVID-19. The study calls for patients to receive Bucillamine 200 mg orally, three times a day for up to 14 days. Patients will be…

Continue Reading

WednesdaySep 16, 2020 11:37 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Announces Strategic Scientific Advisory Board Appointment

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, today announced that Eric Milledge has joined DarioHealth as chairman of the company's newly-established Scientific Advisory Board (“SAB”). Milledge has dedicated his entire career to the field of health care, with a focus on pharmaceuticals and medical devices, and spent 34 years at Johnson & Johnson, building a vast network of relationships across the health-care landscape. "We are very pleased that Eric is spearheading our effort to assemble a world-class SAB," said Dario's CEO Erez Raphael in the press release. "He brings significant experience and knowledge relevant to our industry,…

Continue Reading

MondaySep 14, 2020 3:19 pm

BioMedNewsBreaks – Seelos Therapeutics Inc. (NASDAQ: SEEL) Secures $7M in Registered Direct Offering

Seelos Therapeutics (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, has closed a sale of 8,865,000 shares of common stock with certain institutional investors. According to the update, Seelos Therapeutics secured approximately $7 million in gross proceeds, with each of the shares sold at the price of $0.79. The company also agreed to issue unregistered warrants to the investors to purchase up to 6,648,750 shares of common stock in a concurrent private placement. The warrants have an exercise price of $0.84 per share of common stock, exercisable six months from the date of issuance and with an expiration date five years following…

Continue Reading

MondaySep 14, 2020 12:32 pm

BioMedNewsBreaks – Upcoming Summit to Provide Thought-Provoking Sessions, Interactive Panels for Life Science Professionals

Produced by Lincoln Health Network, the upcoming Strategic HCP/HCO Partnerships Summit is a virtual event that will provide thought-provoking and spotlight sessions and interactive panels. Slated for Nov. 18-20, 2020, the event is specifically designed for life science professionals from pharmaceutical, biotech and medical device organizations. At the 3-day interactive summit, attendees will have the opportunity to enhance their engagement strategy and end-to-end interaction with HCP to drive strategic results while remaining compliant in a digital, physical or hybrid environment. The event already boasts an impressive speaker lineup that organizers continue to update with thought leaders and industry giants. To…

Continue Reading

FridaySep 11, 2020 10:09 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that CEO John Climaco will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference. According to the update, Climaco’s presentation is scheduled to begin at 9:30 a.m. EDT on Wednesday, September 16, 2020, and CNSP management will hold one-on-one virtual investor meetings at the event. Interested parties may register for the presentation by visiting http://ibn.fm/3BGwC . In addition, a replay of the presentation will be available on the company's…

Continue Reading

ThursdaySep 10, 2020 12:09 pm

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Announces Promising Results From Second Preclinical Study of AV-101 – Probenecid Combination

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, recently announced positive new data from the company's second preclinical study of its oral investigational drug, AV-101, in combination with probenecid. According to the update, results of the new study complement previous preclinical data demonstrating the combination's potential to substantially increase the brain concentration of AV-101's active metabolite, 7-Cl-KYN, a potent and selective full antagonist of the NMDA receptor glycine co-agonist site, thereby reducing NMDA receptor signaling. "These new positive results amplify our message that AV-101, when administered in…

Continue Reading

WednesdaySep 09, 2020 11:53 am

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Secures C$13.29M Through Previously Announced Offering

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today confirmed that it has closed its previously announced offering of units for aggregate gross proceeds of approximately C$13.29 million. According to the update, the company issued 15,640,000 units, each at a price of C$0.85, with each unit consisting of one common share of the company and ½ of one common share purchase warrant, with each whole warrant entitling the holder to purchase one share, at the price of C$1.10 per share, until September 9, 2023. “Over the last four years, LexaGene…

Continue Reading